22
Participants
Start Date
September 30, 2007
Primary Completion Date
November 30, 2010
Study Completion Date
November 30, 2010
ARA-C
100 mg/m\^2 IV Daily Over 1 Hour for 4 Days
BCNU
300 mg/m\^2 IV Over 1 Hour for 1 Day
Campath-1H
15 mg IV Daily Over 30 Minutes for 3 Days
Cyclophosphamide
1000 mg/m\^2 IV Daily Over 1 Hour for 3 Days
Etoposide
100 mg/m\^2 IV Daily Over 3 Hours for 4 Days
Fludarabine
30 mg/m\^2 IV Daily Over 1 Hour for 3 Days
Melphalan
100 mg/m\^2 IV Over 30 Minutes for 1 Day.
Rituximab
375 mg/m\^2 IV Over 5-7 Hours for 1 Day, followed by 1000 mg/m\^2 IV Over 5-7 Hours Weekly for 3 Weeks.
Allogeneic Stem Cell Transplantation
Stem Cell Infusion on Day 0.
Total body radiation (TBI)
TBI on Day 5 following chemotherapy, before stem cell infusion.
Methotrexate
5 mg/m2 IV on Days +1, +3, and +6.
Tacrolimus
0.03 mg/kg/day IV starting on Day -2, to be given through day 60, tapered by 20% every week, then discontinue by day 90.
Adback NK or T Cell
Adback natural killer (NK) cells or T cells after transplantation to enhance full engraftment of donor cells. Cell adback after transplantation applies only if there is no active GVHD, and no previous episode of grade II-IV GVHD.
UT MD Anderson Cancer Center, Houston
M.D. Anderson Cancer Center
OTHER